The estimated Net Worth of Richard Daniell is at least $5.51 Million dollars as of 5 March 2024. Mr. Daniell owns over 77,802 units of Teva- Pharmaceutical Industries stock worth over $2,244,928 and over the last 7 years he sold TEVA stock worth over $3,269,728. In addition, he makes $0 as Executive Vice President - European Commercial at Teva- Pharmaceutical Industries.
Richard has made over 20 trades of the Teva- Pharmaceutical Industries stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 98,943 units of TEVA stock worth $1,711,714 on 12 August 2024.
The largest trade he's ever made was selling 98,943 units of Teva- Pharmaceutical Industries stock on 12 August 2024 worth over $1,711,714. On average, Richard trades about 22,758 units every 55 days since 2018. As of 5 March 2024 he still owns at least 124,996 units of Teva- Pharmaceutical Industries stock.
You can see the complete history of Mr. Daniell stock trades at the bottom of the page.
Richard Daniell serves as Executive Vice President - European Commercial of the Company. From December 2016 to November 2017, he served as President and CEO, Teva Europe Generics. From 2015 to 2016, he served as Chief Integration Officer, leading the integration of the Actavis Generics business into Teva. From 2015 to 2016, he served as Chief Operating Officer, Growth Markets (now International Markets). From 2011 to 2015 he served as Cluster General Manager, United Kingdom and Ireland. Mr. Daniell received a B.Sc. degree in chemistry from the University of Auckland, New Zealand.
Richard Daniell is 53, he's been the Executive Vice President - European Commercial of Teva- Pharmaceutical Industries since 2017. There are 16 older and 11 younger executives at Teva- Pharmaceutical Industries. The oldest executive at Teva- Pharmaceutical Industries Ltd. is Gerald Lieberman, 73, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, L3, 6944020.
Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks, and Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include: